Lower Weight Loss Drug Prices: Positive Outlook for Companies, Says Mizuho's Jared Holz

Impact of Lower Drug Prices

• 💡 The recent announcement regarding lower weight loss drug prices is viewed as more positive than negative for companies like Lily and Novo Nordis.
• 🎯 Investors have been modeling for negative pricing in this category, so establishing a clear line is seen as a positive development.
• 📈 While there might be a negative effect on revenue growth next year, the big picture outlook remains positive.

Balancing Price and Access

• ⚖️ The government's goal is to ensure the broadest possible access to these drugs.
• 🚀 If this deal achieves broad access, it could potentially alleviate pressure on drug companies regarding other price negotiations and allow for volume expansion.
• 💰 The market is still projected to be a hundred billion dollar market even with reduced prices, indicating that companies can still achieve significant revenue.

The Growing Obesity Market

• ⚠️ The obesity epidemic in America has surged, with one in every three Americans being obese by definition.
• 🌍 This presents a massive potential patient pool, numbering in the hundreds of millions, with a multiplier effect internationally.
• 📊 Even with lower prices in Europe and Asia, the global market is substantial, potentially approaching a billion people who could benefit.

Market Size and Pricing Scenarios

• 💰 A median price point of $250-$300 per month for 30 million patients easily reaches the hundred billion dollar market mark.
• 📈 This demonstrates that even with price adjustments, the sheer volume of potential users supports a large and valuable market for these drugs.